NCT06952530进行中（未招募）3 期
A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 487
- 试验地点
- 102
- 主要终点
- Change from Baseline in office Systolic Blood Pressure (SBP)
研究概览
简要总结
GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •refer to the GZPL master protocol study for screening eligibility.
排除标准
- •refer to the GZPL master protocol study for screening eligibility.
研究组 & 干预措施
Placebo
Placebo Comparator
Participants receive placebo.
干预措施: Placebo (Drug)
Orforglipron
Experimental
Participants will receive orforglipron orally.
干预措施: Orforglipron (Drug)
结局指标
主要结局
Change from Baseline in office Systolic Blood Pressure (SBP)
时间窗: Baseline to Week 36
次要结局
- Change from Baseline in 24-hour Ambulatory Blood Pressure Monitoring (ABPM) SBP(Baseline to Week 36)
- Percent Change from Baseline in Body Weight(Baseline to Week 36)
- Percent Change from Baseline in Lipids Triglycerides(Baseline to Week 36)
- Percent Change from Baseline in Lipids non-HDL Cholesterol(Baseline to Week 36)
- Percent Change from Baseline in hsCRP Concentration (mg/L)(Baseline to Week 36)
- Percent Change from Baseline in office SBP in Randomized Withdrawal Population(Baseline to Week 36)
- Pharmacokinetics (PK): Steady-State Area under the Concentration Curve (AUC) of Orforglipron(Baseline to Week 36)
研究者
研究点 (102)
Loading locations...
相似试验
进行中（未招募）
3 期
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1HypertensionNCT06948435Eli Lilly and Company487
已完成
3 期
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightOverweight or ObesityOSANCT06649045Eli Lilly and Company712
尚未招募
2 期
Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown PrimaryNCT06869174Zhiguo Luo, MD, PhD50
已完成
2 期
Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal CancerMetastatic Colorectal CancerNCT01991873AIO-Studien-gGmbH387
终止
1 期
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Castration-resistant Prostate CancerNCT04631601Amgen55